Imp-mel: a phase 1 first-in-human dose-finding study of a novel invariant natural killer tcell agonist (inkt) imm60 in advanced melanoma and non-small-cell lung cancer (nsclc)
Regular and Young Investigator Award Abstracts（2022）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要